SHENZHEN, China, April 25, 2025 /PRNewswire/ — X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission ("SEC") on April 25, 2025. The annual report can be accessed on the Company’s investor relations website at https://ir.xiaoyinggroup.com as well as the SEC’s website at https://www.sec.gov.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company’s IR Department at ir@xiaoying.com. 

About X Financial

X Financial (NYSE: XYF) (the "Company") is a leading online personal finance company in China. The Company is committed to connecting borrowers on its platform with its institutional funding partners. With its proprietary big data-driven technology, the Company has established strategic partnerships with financial institutions across multiple areas of its business operations, enabling it to facilitate and originate loans to prime borrowers under a risk assessment and control system.

For more information, please visit: https://ir.xiaoyinggroup.com.

For more information, please contact:

X FinancialMr. Frank Fuya ZhengE-mail: ir@xiaoying.com 

Christensen IR

In ChinaMr. Rene VanguestainePhone: +86-178-1749 0483E-mail: rene.vanguestaine@christensencomms.com 

In USMs. Linda BergkampPhone: +1-480-614-3004Email: linda.bergkamp@christensencomms.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR JANUARY 31st

NEW YORK, Jan. 31, 2025 /PRNewswire/ — The New York Stock Exchange…

Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

– This trial marks the fourth Phase I peptide study for Ascletis…

Bybit x Block Scholes Report: Cautious Crypto Derivatives, WLFI Volatility Persists

DUBAI, UAE, Nov. 4, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency…